TRCT
PEAR

Tower Research Capital (TRC)’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Tower Research Capital (TRC)’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,982
Closed -$6K – 6611
2023
Q1 		$6K Buy
22,982
+14,039
+157% +$12.7K ﹤0.01% 4920
2022
Q4 		$11K Buy
8,943
+2,157
+32% +$4.54K ﹤0.01% 3930
2022
Q3 		$14K Buy
+6,786
New +$11.5K ﹤0.01% 4244
2022
Q2 		– Sell
-728
Closed -$4K – 6839
2022
Q1 		$4K Sell
728
-4,529
-86% -$20.6K ﹤0.01% 5306
2021
Q4 		$33K Buy
5,257
+4,262
+428% +$38K ﹤0.01% 3157
2021
Q3 		$10K Buy
+995
New +$9.84K ﹤0.01% 4377

Tower Research Capital (TRC)'s PEAR Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 22,982 shares — an estimated $6K sold.

Tower Research Capital (TRC) first reported a position in PEAR in Q3 2021 and held it in 6 quarters. The position peaked at $33K in Q4 2021. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

  • Tower Research Capital (TRC) reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 22,982 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $6K.
  • Tower Research Capital (TRC) first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2021 and held it in 6 quarters.
  • Tower Research Capital (TRC)'s Pear Therapeutics, Inc. Class A Common Stock position peaked at $33K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.